Monopar Therapeutics Inc. (MNPR) Dividend History

Company News

• Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

  Monopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

  GlobeNewswire Inc.
• Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

  Monopar Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $19.2 million public offering of its common stock at $16.25 per share. The proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.

  GlobeNewswire Inc.
• Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24

  WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.

  GlobeNewswire Inc.
• Monopar and NorthStar Amend & Extend Collaboration

  Highlights:

  GlobeNewswire Inc.
• Monopar Announces CFO Succession

  WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring.

  GlobeNewswire Inc.